VINCRISTINE SULFATE
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
Prelude TherapeuticsSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Peking University People's Hospital | Phase 2 | BB |
PREDNISONE TABLETS Prelude Therapeutics | Phase 2 | BB |
Inno-206 Prelude Therapeutics | Phase 2 | BB |
Zanubrutinib Prelude Therapeutics | Phase 2 | B |
Venetoclax Prelude Therapeutics | Phase 1/2 | B |
prt2527 Prelude Therapeutics | Phase 1 | CC |
Same molecule, other indications
VINCRISTINE SULFATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →